Blog
RSS FeedPosted by Michael Wonder on 02 Jun 2025
RSV prophylaxis with nirsevimab: benefits for healthy children in the first RSV season
2 June 2025 - Children immunised with the antibody nirsevimab are significantly less likely to develop RSV-related lower respiratory tract infections. ...
Posted by Michael Wonder on 02 Jun 2025
Garadacimab in hereditary angioedema: evidence of considerable additional benefit
2 June 2025 - An indirect comparison shows a significant reduction in the monthly rate of attacks and other benefits. ...
Posted by Michael Wonder on 19 Mar 2025
Linzagolix choline in endometriosis: comparative data are lacking
18 March 2025 - There are no comparative studies with established active ingredients in endometriosis; placebo comparisons are unsuitable for assessing ...
Posted by Michael Wonder on 01 Feb 2025
High quality evidence for the treatment of very rare diseases: IQWiG is involved in the EU project RealiseD
29 January 2025 - Developing clinical studies for good evidence on very rare diseases in order to arrive at effective therapies ...
Posted by Michael Wonder on 23 Jan 2025
EU-HTA: maintaining the achievements of AMNOG
20 January 2025 - IQWiG welcomes the fact that the adjustments to the AMNOG procedure planned for the integration with European ...
Posted by Michael Wonder on 06 Jan 2025
Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: evidence of a significant additional benefit
2 January 2025 - Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new combination of active ingredients ...
Posted by Michael Wonder on 05 Dec 2024
Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs
3 December 2024 - The number of orphan drug approvals has increased sharply in Europe. In Germany, all orphan drugs are ...
Posted by Michael Wonder on 03 Sep 2024
Vadadustat for symptomatic anaemia due to chronic kidney disease: missed opportunity
2 September 2024 - In the two manufacturer studies, important patient-relevant outcomes were not recorded. ...
Posted by Michael Wonder on 12 Aug 2024
Changes in revenues associated with antimicrobial reimbursement reforms in Germany
10 August 2024 - Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and ...
Posted by Michael Wonder on 16 May 2024
Delegation from Taiwan visits IQWiG
15 May 2024 - At the end of April 2024, Mao-Ting Sheen visited the Institute for Quality and Efficiency in Healthcare ...
Posted by Michael Wonder on 02 Apr 2024
Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back
2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...
Posted by Michael Wonder on 04 Mar 2024
Together for high standards in the assessment of health technologies in Europe from 2025
1 March 2024 - A few months before the EU HTA regulation came into force, a delegation from the French HTA ...
Posted by Michael Wonder on 04 Mar 2024
Tebentafusp in uveal melanoma: indication of a considerable additional benefit
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
Posted by Michael Wonder on 01 Feb 2024
Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...
Posted by Michael Wonder on 04 Dec 2023
Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...